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Abstract 
Introduction: 
The C9orf72 repeat expansion has been reported as a negative prognostic factor in amyotrophic 
lateral sclerosis (ALS). Here we have examined the prognostic impact of the C9orf72 repeat 
expansion in European subgroups based on gender and site of onset. 
Methods: 
C9orf72 status and demographic/clinical data from 4925 ALS patients drawn from three 
prospective ALS registers (Ireland, Italy and The Netherlands), and clinical datasets in the UK and 
Belgium. Flexible parametric survival models were built including known prognostic factors (age, 
diagnostic delay and site of onset), gender and the presence of an expanded repeat in C9orf72. 
These were used to explore the effects of C9orf72 on survival by gender and site of onset. 
Individual patient data (IPD) meta-analysis was used to estimate hazard ratios for results of 
particular importance. 
Results: 
457 (8.95%) of 4925 ALS cases carried the C9orf72 repeat expansion. A meta-analysis of C9orf72 
estimated a survival hazard ratio (HR) of 1.36 (1.18 – 1.57) for those carrying the expansion. 
Models evaluating interaction between gender and C9orf72 repeat expansions demonstrated that 
the reduced survival due to C9orf72 expansion was being driven by spinal onset males (HR 1.56 
(95% CI: 1.25 – 1.96). 
Conclusions: 
This study represents the largest combined analysis of the prognostic characteristics of the 
C9orf72 expansion. We have shown for this first time that the negative prognostic implication of 
this variant is driven by males with spinal onset disease, indicating a hitherto unrecognized 
gender-mediated effect of the variant that requires further exploration. .  
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a debilitating disease with a poor prognosis. Progress 
towards developing new treatments has been limited both by disease heterogeneity, and by the 
likely interaction between genetic and environmental factors in disease pathogenesis1. A 
pathological expansion of a hexanucleotide repeat in the C9orf72 gene2,3 accounts for up to 10% 
of those with ALS in populations of European extraction, and is associated with a distinctive clinical 
phenotype that includes fronto-temporal dementia in some instances4–10. Although the C9orf72 
repeat expansion has been shown to be an important negative prognostic factor in survival 
analyses4–10, to date no study has been sufficiently large to permit robust analysis of interactions 
between the variant and demographic features including age, gender and site of onset. Here we 
used our combined clinical datasets to determine whether the presence of the expanded variant 
differentially modulates survival based on gender and site of onset.   
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Methods 
Data sources /Case capture 
Clinical data from ALS cases incident from January 2000 to April 2015 were collected from 
Belgium, Ireland, Italy, The Netherlands and the United Kingdom. All patients fulfilled the 
diagnostic criteria for ALS, and core data elements as defined by the ENCALS consortium were 
harmonised across data-sets for consistency based on existing consortia agreements11. Due to the 
lack of an agreed international definition of 'familial ALS', and given a previous population based 
familial aggregation analysis from Ireland demonstrated a much higher familial ALS occurrence 
(16%) than usually recognised 12, we did not exclude cases based on family history. The Belgian 
and UK cases were collected from clinical research centre cohorts, while the Dutch, Irish and 
Italian cases were sourced from the prospective population based national registers13–19 . 
In accordance with existing Consortia agreements, data were collated using the following 
variables: age of onset, date of onset, date of diagnosis, date of death / last known follow-up date, 
site of onset, revised El-Escorial diagnostic category (except Belgium), and C9orf72 status (normal 
or expanded). For all study participants, C9orf72 status was determined by repeat-primed PCR as 
described previously (with individual laboratory-based validation and quality control by Southern 
blot analyses)3.  
Survival analysis strategy 
Initially exploratory models were constructed using Cox proportional hazards regression to explore 
the effect of different time of entry to the studies. Cox models were generated including known 
important survival covariates including age of onset, site of onset, diagnostic delay and C9orf72. 
Cox models were compared using a likelihood ratio test, and by testing the validity of the 
proportional hazards assumption of each covariate at each timescale.  
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.A base model using Royston-Parmar flexible parametric regression20 was built on the preferred 
timescale, with a proportional hazards scale and a number of degrees of freedom selected by 
comparison of the AIC (Akaike Information Criterion) and BIC (Bayesian Information Criterion) 
from models with increasing degrees of freedom, and the variance covariance matrix clustered by 
country. Survival follow-up was limited to 5 years from entry. Models were then built to explore 
the effect of C9orf72 status in sex and site of onset subgroups. The stpm221 and ipdmetan22 
commands from Stata MP 14.0 were used to perform the survival analysis and produce the meta-
analysis graphs, whilst the ggplot223 package in R 3.1.1 was used to generate selected final graphs.  
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Results 
Descriptive statistics and basic survival model 
In total, 5,106 ALS cases met the inclusion criteria, of which 457 (8.95%) carried the C9orf72 
repeat expansion. Breakdown of the demographics of the overall cohort by country is shown in 
table 1. Missing values were minimal affecting 181 cases (3.5%).  Supplementary information 1 
summarizes the basic survival model. An individual patient data (IPD) meta-analysis of C9orf72 
status in the base model estimated a hazard ratio of 1.36 (1.18 – 1.57) for those carrying the 
expansion vs those not.  
 
C9orf72, gender and site of onset subgroup analysis 
Survival curves were generated to evaluate the effect of C9orf72 status on gender and site of 
onset (Fig 1) which suggested three-way interaction. Therefore gender, site of onset and C9orf72 
status were categorised into one variable with eight levels as demonstrated in Table 1. Through 
comparison of survival curves, redundant sub-groups were combined (Supplementary Information 
2) leaving 3 groups: spinal onset males with the C9orf72 expansion, other spinal onset patients, 
and all bulbar onset patients. Survival curves for these groups showed that male spinal onset 
patients with the C9orf72 repeat expansion had a prognosis distinct from other spinal onset 
patients and similar to bulbar onset patients (Fig 2). Meta-analysis calculated a survival hazard 
ratio of 1.56 (95% CI: 1.25 – 1.96) for this group (figure 3). Adjustment for El Escorial category did 
not substantially alter the hazard ratio ( 1.57 CI:1.26 – 1.97). The finding was in the same direction 
in each country, although only the pooled estimate was statistically significant (figure 3).  
The median ages and distribution of diagnostic delay across the final sub-groups is shown in Table 
2. While age of onset was oldest in the bulbar onset group and youngest in the male spinal onset 
C9orf72 expanded group, the male spinal onset C9orf72 expanded group also had the highest 
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proportion in the “short” diagnostic delay category, consistent with the finding that the C9orf72 
expansion differentially affects disease course in a gender specific manner.  
 
 
Discussion 
Previously, studies have shown that people with ALS carrying a C9orf72 repeat expansion in blood  
present at a younger age and have reduced survival when compared to patients without the 
expanded variant (Table 4).  However, studies to date have not been sufficiently powered to 
determine whether the expanded variant differentially affects outcome in subgroups based on 
gender and site of onset. Our findings demonstrate an intriguing and previously unrecognized 
interaction between the expanded variant and male patients with spinal onset disease, which 
appears to drive the overall survival effect. Within this cohort, the median age of onset was 59.3 
and the median survival was 2.29 years. This compared to a median age of onset of 62.3 and 
median survival of 2.77 yrs in all other spinal onset disease, and a median age of onset of 65 and 
median survival of 2.38 years in all bulbar onset disease. Moreover, and contrary to the usual 
pattern in young onset disease, male spinal onset C9orf72 expanded cases were also more likely to 
have experienced a shorter diagnostic delay, suggesting rapidly progressing disease. 
Gender has previously been reported as an independent predictor of functional decline in ALS24, 
however our observation of an interaction between site of onset and gender has not been 
previously noted possibly due to limitations in the  power of previous studies due to lower 
numbers (Table 4).  Taken together, our findings and those of previous  studies imply that distinct 
processes may operate in differing subgroups of ALS even when a known genetic factor is present 
as the underlying cause, and demonstrate that male gender is likely to be an important interacting 
factor in the biology of C9orf72 related disease.   
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A number of pathogenic mechanisms have been proposed to explain the role of the C9orf72 
repeat expansion in ALS. These include haplo-insufficiency, toxic RNA interfering with the function 
of RNA-binding proteins or other cellular factors, and the presence of toxic dipeptide repeat 
proteins through RAN translation25,26. Recent work has pointed also towards C9orf72 induced 
pathology of nucleocytoplasmic transport processes26–29.  However, the pathobiology of the 
observed interaction between the C9orf72 variant and gender remains unclear, but it is congruent 
with observations in the SOD1 mouse model, in which transgenic mutant males have shorter 
survival compared to their transgenic female littermates with similar copy numbers30. The 
mechanism for this gender effect in animals, although well recognized has not been characterized, 
but can be attenuated when mice are bred on a different genetic background30. 
A potential weakness of our study is that it did not include clinical scores for the presence of 
cognitive change, which is a known prognostic indicator in ALS. We and others have shown that 
those with C9orf72 repeat expansions are more likely to experience cognitive and behavioural 
change, however to our knowledge to date, no gender mediated effect has been demonstrated in 
C9orf72 related cognitive profiling. Moreover, as C9orf72 is part of the causal pathway for some 
forms of FTD, inclusion of cognitive status as a variable would have introduced a selection bias 
based on ‘conditioning on a common effect’31.  A further limitation to this study is that our 
analysis does not include C9orf72 repeat expansion analysis by Southern blot, although Individual 
definition of pathological expansion performed by each centre using repeat primed PCR was 
validated by Southern blot. While the length of expansion varies from tissue to tissue32–34,  
diagnostic testing within a clinical setting uses blood samples from which all previous prognostic 
and clinical correlative studies have been performed.   
In conclusion, we have performed an analysis of the effect of the C9orf72 expansion on survival in 
almost 5000 European ALS patients. We have shown for the first time that C9orf72 repeat 
expansion is a significant negative prognostic indicator in males with spinal onset disease only. . 
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These findings suggest a hitherto unrecognized interaction between the C9orf repeat expansion, 
site of onset and gender. This has important implications in understanding both the pathobiology 
of C9orf-mediated disease, and in the development of future disease-related prognostic models. 
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Table 1 – Baseline demographics of C9orf72-tested ALS cases by country 
 
Variable Belgium 
n = 482 
Ireland 
n = 645 
Italy 
n = 897 
The 
Netherlands 
n = 2153 
United 
Kingdom 
n= 929 
P (Chi
2) 
Combined 
N = 5106 
Included after 
missing values 
removed 
477 
(99.0%) 
640 
(99.2%) 
867 
(96.7%) 
2037 
(94.6%) 
904 
(97.3%) 
 4925 
(96.5%) 
Sex        
Female 180 
(37.3) 
266 
(41.6%) 
411 
(47.4%) 
844 
(41.4%) 
352 
(38.9%) 
 2053 
(41.7%) 
Male 297 
(62.3) 
374 
(58.4%) 
456 
(52.6%) 
1193 
(58.6%) 
552 
(61.1%) 
<0.001 2872 
(58.3%) 
        
Age of Onset        
Median 61.4 63.0 66.8 63.0 61.3  63.1 
        
Diagnostic 
Delay  
       
Short 161 
(33.8%) 
193 
(30.2%) 
285 
(32.9%) 
702 
(43.5%) 
300 
(33.2%) 
 1641 
(33.3%) 
Medium 163 
(34.2%) 
211 
(33.0%) 
293 
(33.8%) 
683 
(33.5%) 
298 
(33.0%) 
 1648 
(33.5%) 
Long 153 
(32.1%) 
236 
(36.9%) 
289 
(33.3%) 
652 
(32%) 
306 
(33.8%) 
0.559 1636 
(33.2%) 
        
Site of Onset        
Spinal 326 
(68.3%) 
437 
(68.3%) 
583 
(67.2%) 
1333 
(65.4%) 
610 
(67.5%) 
 3289 
(66.8%) 
Bulbar 151 
(31.7%) 
203 
(31.7%) 
284 
(32.8%) 
704 
(34.6%) 
294 
(32.5%) 
 
0.540 
1636 
(33.2%) 
        
        
C9orf72        
Normal 392 
(82.2%) 
578 
(90.3%) 
805 
(92.8%) 
1861 
(91.4%) 
841 
(93.0%) 
 4477 
(90.9%) 
Expanded 85 
(17.8%) 
62 
(9.7%) 
62 
(7.2%) 
176 
(8.6%) 
63 
(7%) 
<0.001 448 
(9.1%) 
        
Table 1 Legend: 
Diagnostic delay is defined by three tertiles per country labeled “short”, “medium” and “long” 
diagnostic delay to allow for variation in diagnostic delay between countries. 
¶ Kruskal-Wallis test 
IQR = inter-quartile range 
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Table 2.  Age of onset and diagnostic delay for hybrid sex/site of onset / C9 variable 
Level Age at onset 
 
 Diagnostic delay 
 Median 
(IQR) 
 Short Medium Long 
Spinal onset 
excluding C9orf72 
expanded males 
62.3 
(54.0 – 69.7) 
 965 
(30.8%) 
1014 
(32.4%) 
1151 
(36.8%) 
All bulbar onset 65.0 
(58.4 – 71.9) 
 611 
(37.4%) 
590 
(36.1%) 
435 
(26.6%) 
Male spinal onset 
C9orf72 only 
59.3 
(52.3 – 64.7) 
 65 
(40.8%) 
44 
(27.7%) 
50 
(31.5%) 
P value  0.0001
¶
  <0.001† 
¶ Kwallis test 
† Chi2 test  
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Table 3 – Hazard ratios for El Escorial criteria after inclusion in final model 
El Escorial Category HR 95% CI Wald test 
Suspected 0.86 0.68 – 1.08 0.199 
Possible 1 - - 
Probable – Lab supported 1.38 1.31 – 1.44 <0.001 
Probable 1.49 1.39 – 1.60 <0.001 
Definite 2.09 1.99 – 2.21 <0.001 
Sex/Site of onset/C9orf72    
Spinal onset excluding male C9orf72 
expanded cases 
1 - - 
All bulbar onset cases 1.33 1.21 – 1.45 <0.001 
Male C9orf72 expanded cases only 1.57 1.26 – 1.96 <0.001 
 
Table 3 Legend:  
Hazard ratios for each of the El Escorial criteria from a Royston Parmar model on the hazard scale 
with 3 degrees of freedom and including age of onset (time varying), diagnostic delay, site of 
onset, country and sex-site-C9 as a hybridized variable with variance-covariance matrix allowed to 
pool by country. Note that Belgium was omitted as the El-Escorial criteria was not available, the 
UK data included only Probable and Definite category ALS, whilst Ireland does not use the 
“Probable lab supported” category as shown in table 1. Nevertheless, hazard ratios are in line with 
expectations showing a gradually increasing hazard with increasing category severity. 
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Table 4 – Summary of previous analyses of survival by C9orf72 status 
Study Population C9orf72 
Normal 
C9orf72 
Expanded 
Median 
survival 
delta¶ 
Median age 
at onset 
delta¶ 
HR 
(CI) 
Byrne et 
al4 
Ireland 170 21 -6 months -3.2 yrs 1.9 
(1.1 – 3.7) 
Van 
Rheenen 
et al5 
The 
Netherlands 
1422 78 -2.5 months -2.6 yrs 1.46 
(1.17 – 1.83) 
Sabatelli 
et al6 
Italy & Sardinia 1688 69 -1 yr -3.8 yrs 1.79 
(1.26 – 2.98) 
Borghero 
et al7 
Sardinia 375 51 -1.5 yrs ¶¶ -0.9yrs na 
Debray et 
al8 
Belgium 513 77 fALS -38.3 
months 
sALS -5.8 
months 
fALS -5.9 yrs 
sALS -0.3 yrs 
fALS 2.5 
(1.5 – 4.3) 
sALS 1.1 
(0.8 – 1.5) 
Garc´ıa-
Redondo 
et al9 
Spanish 936 67 -12 months -2.6 yrs ¶¶¶  na 
Irwin et 
al10 ¶¶¶¶ 
United States 
(Pennsylvania) 
69 64 -6 
months¶¶¶ 
-3.0 yrs ¶¶¶ na 
 
¶ Negative figures imply C9orf72 expanded survive for shorter time, or are younger at onset than 
C9orf72 normal cases 
¶¶ Calculate as median survival in C9orf72 expanded group – median survival in overall cohort 
median 
¶¶¶ Calculated from mean data instead of median 
¶¶¶¶ Mixed ALS & FTD cases 
fALS = familial ALS ; sALS = sporadic ALS 
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Figure 1 – Predicted survival by sex and C9orf72 status after multivariate Royston-Parmar 
regression including interaction terms 
 
 
Figure 1 Legend: C9 Normal = group not carrying the C9orf72 expansion; C9 Exp. = group carrying 
the C9orf72 expansion present. Shaded areas represent 95% confidence intervals. 
Predicted survival curves for interaction models between gender and C9orf72 status (upper), and 
site of onset and C9orf72 status (lower) after multivariate regression using a Royston Parmar 
model on the hazard scale (3 d.f.), correcting for age of onset (time varying), diagnostic delay 
group (time varying), site of onset, country and using a variance-covariance matrix clustered by 
country. The upper graph shows a wider spread by C9orf72 status in males compared to females, 
while the lower shows a wider spread in spinal onset cases vs bulbar onset cases – however 
hazard ratios for these interactions were not significant.  
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Figure 2 - Predicted survival function for male spinal onset C9orf72 expanded patients 
 
 
Figure 2 legend: C9 exp. = group carrying the C9orf72 expansion. Shaded areas represent 95% 
confidence intervals. 
Survival curves show three subgroups of patients categorized by sex, site of onset and C9orf72 
status. Survival curves for male spinal onset patients with the C9orf72 repeat expansion are 
markedly worse than other spinal onset patients and are in fact inseparable from bulbar onset 
patients. Median predicted survival in the three groups were: Spinal excluding C9orf72 expanded 
males 2.77 (95%CI 2.67 – 2.87); bulbar onset 2.38 (95% CI 2.33 – 2.42); spinal onset males with 
C9orf72 repeat expansion 2.29 (95%CI 2.15 – 2.49).  
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Figure 3 - Individual Patient Data meta-analysis of the hazard ratio of male spinal onset ALS 
patients carrying the C9orf72 repeat expansion 
 
 
Figure 3 legend: C9orf72exp. = group carrying the C9orf72 expansion. 
IPD meta-analysis of C9orf72 repeat expansion in male spinal onset ALS patients versus spinal 
onset C9orf72 normal patients pooled by country and analysed using a Royston-Parmar flexible 
parametric model with 3 degrees of freedom on the hazard scale correcting for age at onset (time 
varying), site of onset and diagnostic delay, based on the 3 level categorical breakdown of sex, 
site, and C9orf72 status described in Suppl. Info. 2. 
